The safety of dipeptidyl peptidase 4 inhibitors and the risk for heart failure

JAMA Cardiology

Volumn 1, Issue 2, 2016, Pages 123-125

  Scirica, Benjamin M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; LIRAGLUTIDE; LIXISENATIDE; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN; ADAMANTANE; ANTIDIABETIC AGENT;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR DISEASE; DRUG SAFETY; EDITORIAL; ESTIMATED GLOMERULAR FILTRATION RATE; GLYCEMIC CONTROL; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART PROTECTION; HOSPITALIZATION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; SIDE EFFECT;

ADAMANTANE; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 85015830814     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2016.0184     Document Type: Editorial

References (15)

1. Mulvihill EE, Drucker DJ. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev. 2014; 35(6): 992-1019.
2. Monami M, Ahrén B, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013; 15(2): 112-120.
3. Scirica BM, Bhatt DL, Braunwald E, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369(14):1317-1326.
4. White WB, Cannon CP, Heller SR, et al.; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013; 369(14):1327-1335.
5. Green JB, Bethel MA, Armstrong PW, et al.; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015; 373(3):232-242.
6. Pfeffer MA, Claggett B, Diaz R, et al.; ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015; 373(23):2247-2257.
7. Scirica BM, Braunwald E, Raz I, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014; 130(18):1579-1588.
8. Zannad F, Cannon CP, Cushman WC, et al.; EXAMINE Investigators. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015; 385(9982):2067-2076.
9. McGuire DK, Van de Werf F, Armstrong PW, et al.; Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) Study Group. Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial [published online April 13, 2016]. JAMA Cardio. doi:10.1001/jamacardio.2016.0103.
10. Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Scirica BM. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2015; 3(5):356-366.
11. Fadini GP, Avogaro A, Degli Esposti L, et al.; OsMed Health-DB Network. Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database. Eur Heart J. 2015; 36(36):2454-2462.
12. Kim SC, Glynn RJ, Liu J, Everett BM, Goldfine AB. Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study. Acta Diabetol. 2014; 51(6): 1015-1023.
13. McMurray JJ, Ponikowksi P, Bolli GB, et al. Vildagliptin in Ventricular Dysfunction Diabetes Trial (VIVIDD). Eur J Heart Fail. 2013; 12(suppl 1).
14. Margulies KB. A Randomized Trial of Liraglutide for High-Risk Heart Failure Patients with Reduced Ejection Fraction (FIGHT)-NHLBI Heart Failure Clinical Research Network. Paper presented at: American Heart Association Scientific Sessions 2015; November 10, 2015; Orlando, Florida. http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm-479142.pdf. Accessed March 10, 2016.
15. Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373(22):2117-2128.